Streetbeat News

Stock Prices

QNTUSD

Quant (CRYPTO: QNT) has seen a significant price drop of 7.15% in the past 24 hours, reaching $120.01, and an 11% decrease over the past week from $134.92. The trading volume has decreased by 25%, while the circulating supply has slightly increased. Quant's market cap ranking is currently #47, with a valuation of $1.75 billion.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:02 pm

GRTUSD

The Graph's cryptocurrency (GRT) has seen a 7.23% decrease in price over the last 24 hours, continuing a negative trend from the past week with a 1.0% loss. The trading volume for GRT has increased by 17.0% over the past week, while the circulating supply rose by 0.15% to 9.36 billion, approximately 86.8% of its max supply. The Graph is currently ranked #48 in market cap at $1.70 billion.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:02 pm

NEM

Benzinga's options scanner revealed significant bullish options activity on Newmont (NYSE:NEM), with 55% bullish sentiment among 9 trades. The options indicate a targeted price range of $30.0 to $42.5. Newmont, the world's largest gold miner, recently acquired Newcrest and is expected to produce 7.3 million ounces of gold in 2023. The stock is slightly up with a potential overbought RSI indicator, and UBS maintains a Neutral rating with a $40 target price.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:01 pm

TW

Tradeweb Markets (NASDAQ:TW) has been analyzed by 10 analysts in the last three months, with a diverse range of perspectives. The recent assessments show a shift towards a more bullish outlook, with the average 12-month price target raised to $96.5, up from the previous $90.10. Analysts from firms like Raymond James, UBS, Morgan Stanley, Rosenblatt, JP Morgan, Deutsche Bank, Barclays, and Piper Sandler have raised their price targets for TW, indicating a positive sentiment towards the company's performance and market position.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:01 pm

CHGG

The Bear Cave released a report suggesting Chegg, Inc. (NYSE:CHGG) is facing significant challenges from AI-powered homework helpers, potentially leading to its downfall. Chegg's stock has already dropped nearly 60% over the past year. The company's CEO acknowledged the impact of AI competitors like ChatGPT, and Chegg is pivoting to focus on its own AI chatbot, CheggMate. Additionally, Chegg has been criticized for its cancellation process, leading to poor customer reviews and complaints.

Portfolio Pulse from Erica Kollmann

January 05, 2024 | 7:00 pm

ROP

Over the past 20 years, Roper Technologies (NASDAQ:ROP) has delivered an average annual return of 16.23%, outperforming the market. A $100 investment in ROP 20 years ago would be worth $2,004.97 today. Roper Techs currently has a market cap of $55.99 billion.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:00 pm

COR

Cencora (NYSE:COR) has delivered an average annual return of 14.73% over the past 20 years, outperforming the market by 7.34% annually. A $100 investment in COR stock 20 years ago would be worth $1,529.38 today. Cencora's market capitalization currently stands at $42.01 billion.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:00 pm

PCVX

PHAT

Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT), raising the price target to $26 from $23 and adding it to the Needham Conviction List. Phathom's stock is expected to perform strongly in 2024 due to the launch of Voquezna in Erosive GERD and its anticipated approval and launch in Non-Erosive GERD (NERD). The analyst projects $55.6 million in Voquezna sales for 2024, which is above the consensus estimate of $46 million. Voquezna is seen as a potential best-in-class acid blocker with significant peak sales potential in various indications. Phathom's cash runway is expected to last through 2026, covering multiple value-driving events. PHAT shares recently traded slightly lower at $8.98.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 6:52 pm

TRDA

Entrada Therapeutics' stock price has risen following Oppenheimer's initiation of coverage with an Outperform rating and a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 6:51 pm

PTON

Peloton Interactive's stock is trading higher following the announcement of an exclusive partnership with TikTok to deliver Peloton's workout content to the TikTok user base.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 6:47 pm